OUTCOME OF AZACITIDINE TREATMENT AND INCIDENCE OF FEBRILE EVENTS IN "REAL WORLD" PATIENTS WITH MDS OR LOW-BLAST COUNT AML

被引：0
|
作者：
Voso, M. T. [1 ]
Niscola, P. [2 ]
Piciocchi, A. [3 ]
Fianchi, L. [4 ]
Maurillo, L. [1 ]
Musto, P. [5 ]
Pagano, L. [4 ]
Mansueto, G. [5 ]
Criscuolo, M. [4 ]
Aloe-Spiriti, M. A. [6 ]
Buccisano, F. [1 ]
Venditti, A. [1 ]
Tendas, A. [2 ]
Piccioni, A. L. [7 ]
Zini, G. [4 ]
Latagliata, R. [8 ]
Filardi, N. [9 ]
Fragasso, R. [10 ]
Fenu, S. [11 ]
Breccia, M. [8 ]
机构：
[1] Univ Roma Tor Vergata, Hematol Biomed & Prevent, Rome, Italy
[2] S Eugenio Hosp, Hematol, Rome, Italy
[3] Univ Roma La Sapienza, Stat Sci, I-00185 Rome, Italy
[4] Univ Cattolica Sacro Cuore, Hematol, Rome, Italy
[5] IRCCS CROB MDS Registry Basilicata, Hematol, Rionero In Vulture, Pz, Italy
[6] S Andrea Hosp, Hematol, Rome, Italy
[7] S Pertini Hosp, Hematol, Rome, Italy
[8] Univ Roma La Sapienza, Hematol, I-00185 Rome, Italy
[9] S Carlo Hosp MDS Registry Basilicata, Hematol, Potenza, Italy
[10] Madonna delle Grazie Hosp MDS Registry Basilicata, Hematol, Matera, Italy
[11] S Giovanni Hosp, Hematol, Rome, Italy
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30199-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
198
引用
收藏
页码：S99 / S99
页数：1
相关论文
共 44 条
  • [21] Efficacy and Safety Analysis of Venetoclax Combined with Azacitidine in Real-World Treatment of Patients with AML
    Huang, Xin
    Deng, Chengxin
    Li, Minming
    Lu, Zesheng
    Wu, Ping
    Luo, Qiong
    Geng, Suxia
    Zeng, Lingji
    Wang, Yulian
    Zhou, Hui
    Weng, Jianyu
    Du, Xin
    BLOOD, 2023, 142
  • [22] Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)
    Kenealy, Melita
    Patton, Nigel
    Filshie, Robin
    Nicol, Andrew
    Ho, Shir-Jing
    Hertzberg, Mark
    Mills, Tony
    Prosser, Ian
    Link, Emma
    Cowan, Linda
    Zannino, Diana
    Seymour, John F.
    LEUKEMIA & LYMPHOMA, 2017, 58 (02) : 298 - 307
  • [23] Phase 2 Study of Pevonedistat plus Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS
    Watts, Justin
    Ades, Lionel
    Radinoff, Atanas
    Arnan Sangerman, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S323 - S324
  • [24] Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
    Sebert, Marie
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    Prebet, Thomas
    Cluzeau, Thomas
    Santini, Valeria
    Gyan, Emmanuel
    Sanna, Alessandro
    Ali, Najla Hai
    Hobson, Sean
    Eclache, Virginie
    List, Alan
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2017, 63 : 72 - 77
  • [25] Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)
    Giagounidis, A.
    Ades, L.
    Watts, J.
    Radinoff, A.
    Arnan Sangerman, M.
    Cerrano, M.
    Font Lopez, P.
    Zeidner, J.
    Diez Campelo, M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhao, D.
    Bell, J.
    Friedlander, S.
    Faller, D. V.
    Sekeres, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 171 - 171
  • [26] Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
    Prebet, Thomas
    Charbonnier, Aude
    Gelsi-Boyer, Veronique
    Mozziconacci, Marie Joelle
    Blaise, Didier
    Vey, Norbert
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1538 - 1540
  • [27] Azacitidine in the "real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada
    Mozessohn, Lee
    Cheung, Matthew C.
    Fallahpour, Saber
    Gill, Tripat
    Maloul, Asmaa
    Zhang, Liying
    Lau, Olivia
    Buckstein, Rena
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (06) : 803 - 815
  • [28] Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia
    Voso, Maria Teresa
    Niscola, Pasquale
    Piciocchi, Alfonso
    Fianchi, Luana
    Maurillo, Luca
    Musto, Pellegrino
    Pagano, Livio
    Mansueto, Giovanna
    Criscuolo, Marianna
    Aloe-Spiriti, Maria Antonietta
    Buccisano, Francesco
    Venditti, Adriano
    Tendas, Andrea
    Piccioni, Anna Lina
    Zini, Gina
    Latagliata, Roberto
    Filardi, Nunzio
    Fragasso, Alberto
    Fenu, Susanna
    Breccia, Massimo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (04) : 344 - 351
  • [29] Phase II study of pevonedistat (P) plus azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
    Ades, Lionel
    Watts, Justin M.
    Radinoff, Atanas
    Arnan, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua F.
    Diez-Campelo, Maria
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Faller, Douglas, V
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Outcomes of Induction with Venetoclax in Combination with Decitabine, Azacitidine, or Low-Dose Cytarabine for Treatment of AML: A Real-World Retrospective Analysis
    Bouligny, Ian M.
    Maher, Keri R.
    BLOOD, 2021, 138
12345